Healthcare / Diagnostics & ResearchHKSE
$1.05
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-179.6M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.1B
P/E
N/A
•EV/EBITDA
14.0x
↑ROE
-2.2%
↓Gross Margin
44.0%
↓Debt/Equity
0.15
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.4%
FCF CAGR
—
FCF margin
4.7%
FCF / Net income
-0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $933.6M · net income $-58.7M · FCF $43.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $933.6M | $933.6M | $927.6M | $967.3M | $1.39B |
| Net Income | $-58.7M | $-58.7M | $-54.6M | $41.3M | $75.5M |
| EBITDA | $80.0M | $80.0M | $28.5M | $126.4M | $150.7M |
| EPS | — | — | -0.06 | 0.04 | 0.09 |
| Gross Margin | 44.0% | 44.0% | 47.4% | 46.6% | 43.5% |
| Operating Margin | -8.9% | -8.9% | -3.9% | -4.4% | 5.1% |
| Net Margin | -6.3% | -6.3% | -5.9% | 4.3% | 5.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.15 | 0.15 | 0.14 | 0.07 | 0.07 |
| Current Ratio | 2.81 | 2.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $43.6M | $43.6M | $-179.6M | $-189.7M | $-102.9M |
| Returns | |||||
| ROE | -2.2% | -2.2% | -2.0% | 1.4% | 2.7% |
| Valuation | |||||
| P/E | — | — | — | 40.24 | 28.85 |
| EV/EBITDA | 13.97 | 13.97 | 39.50 | 3.02 | 11.25 |
| P/B | 0.40 | 0.40 | 0.40 | 0.58 | 0.77 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | -4.1% | -30.2% | — |
| EPS Growth | — | — | -235.8% | -53.9% | — |
| Dividend Yield | 9.1% | 9.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → n/d
Residual
-20.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.